0R15 8884.0068 1.4156% 0R1E 9171.0 0.4381% 0M69 None None% 0R2V 255.53 6.2495% 0QYR 1619.0 1.9521% 0QYP 439.6 -0.2043% 0RUK None None% 0RYA 1532.0 -4.0701% 0RIH 190.8 0.0% 0RIH 193.5 1.4151% 0R1O 226.72 9954.102% 0R1O None None% 0QFP None None% 0M2Z 255.4879 -0.0829% 0VSO 33.09 -7.0636% 0R1I None None% 0QZI 599.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 227.3 2.2952%
Last update at 2024-12-23T09:35:00Z
Creo Medical Group "really pleased" with first human trial of lung lesion treatment
Fri 26 May 23, 03:07 PMCreo Medical Group "gaining a level of acceptance" in endoscopy
Tue 23 May 23, 03:15 PMMarket Cool On Creo Medical Group PLC's (LON:CREO) Revenues
Mon 15 May 23, 08:56 AMBullish insiders bet UK£2.1m on Creo Medical Group PLC (LON:CREO)
Mon 24 Apr 23, 05:33 AMCreo Medical Limited (LON:CREO) is favoured by institutional owners who hold 73% of the company
Mon 29 Aug 22, 05:25 AMThe past year for Creo Medical (LON:CREO) investors has not been profitable
Tue 19 Jul 22, 10:32 AMIs Creo Medical (LON:CREO) A Risky Investment?
Sat 04 Jun 22, 09:45 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -30.97700M | -30.33900M | -23.46180M | -18.61538M | -17.57619M |
| Minority interest | - | - | - | - | - |
| Net income | -26.93600M | -24.59500M | -20.31573M | -15.91115M | -14.80861M |
| Selling general administrative | 43.93M | 41.54M | 27.12M | 19.01M | 17.94M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13.12M | 11.59M | 4.03M | 0.00495M | - |
| Reconciled depreciation | 3.11M | 2.56M | 1.60M | 0.64M | - |
| Ebit | -30.75600M | -29.90700M | -23.03717M | -18.87538M | -11.77586M |
| Ebitda | -27.57800M | -27.31400M | -21.24561M | -17.92236M | - |
| Depreciation and amortization | 3.18M | 2.59M | 1.79M | 0.95M | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -30.75600M | -29.90700M | -23.03717M | -18.87538M | -17.66379M |
| Other operating expenses | 57.92M | 55.07M | 32.47M | 18.89M | 0.19M |
| Interest expense | 0.29M | 0.46M | 0.17M | 0.05M | 0.00000M |
| Tax provision | -4.04100M | -5.74400M | -3.14608M | -2.70423M | -2.76758M |
| Interest income | 0.07M | 0.03M | 0.18M | 0.31M | 0.09M |
| Net interest income | -0.22100M | -0.33200M | 0.00522M | 0.29M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -4.04100M | -5.74400M | -3.14608M | -2.70423M | -1.84505M |
| Total revenue | 27.17M | 25.16M | 9.43M | 0.01M | - |
| Total operating expenses | 43.88M | 41.49M | 27.07M | 18.88M | 11.78M |
| Cost of revenue | 14.05M | 13.58M | 5.39M | 0.00852M | - |
| Total other income expense net | -0.22100M | -0.43200M | -0.42464M | 0.26M | 0.06M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -26.93600M | -24.59500M | -20.31573M | -15.91115M | -9.87241M |
| Net income applicable to common shares | - | -24.59500M | -20.31573M | -15.91115M | -9.87241M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 75.34M | 100.61M | 93.50M | 88.26M | 49.75M |
| Intangible assets | 8.08M | 8.69M | 10.27M | 0.87M | 0.31M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 9.13M | 8.61M | 4.32M | - |
| Total liab | 25.93M | 27.29M | 30.70M | 5.60M | 2.03M |
| Total stockholder equity | 49.40M | 73.32M | 62.81M | 82.66M | 47.71M |
| Deferred long term liab | - | 0.36M | 0.49M | 0.12M | 0.15M |
| Other current liab | 2.87M | 4.22M | 4.07M | 3.96M | 0.10M |
| Common stock | 0.18M | 0.18M | 0.16M | 0.15M | 0.12M |
| Capital stock | 0.18M | 0.18M | 0.16M | 0.15M | - |
| Retained earnings | -122.69600M | -95.76000M | -71.16491M | -50.84919M | -34.93804M |
| Other liab | - | 2.38M | 2.32M | - | - |
| Good will | 19.56M | 18.56M | 18.26M | - | - |
| Other assets | - | 2.21M | 1.08M | 0.13M | 0.02M |
| Cash | 13.10M | 43.53M | 45.09M | 81.05M | 44.59M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 17.48M | 19.74M | 21.84M | 5.06M | 1.64M |
| Current deferred revenue | - | 0.21M | 2.00M | - | - |
| Net debt | -1.41400M | -32.97800M | -32.73689M | -80.33136M | - |
| Short term debt | 5.62M | 5.38M | 5.81M | 0.17M | 0.04M |
| Short long term debt | 1.59M | 4.71M | 5.19M | 0.17M | 0.04M |
| Short long term debt total | 11.68M | 10.56M | 12.35M | 0.72M | 0.39M |
| Other stockholder equity | 171.92M | 168.90M | 133.81M | 133.36M | 16.70M |
| Property plant equipment | - | 8.60M | 3.38M | 1.30M | 0.91M |
| Total current assets | 33.69M | 61.17M | 60.51M | 86.09M | 48.51M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 46.42M | 34.77M | 81.92M | 47.41M |
| Short term investments | - | - | - | - | - |
| Net receivables | 6.76M | 8.76M | 8.37M | 4.08M | 3.32M |
| Long term debt | 4.89M | 3.79M | 5.16M | 0.36M | 0.35M |
| Inventory | 9.32M | 8.50M | 6.81M | 0.73M | 0.30M |
| Accounts payable | 9.00M | 9.92M | 9.96M | 4.88M | 0.74M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -1.50659M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.16M | 0.15M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.27M | 0.15M | 0.61M | 0.00840M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 41.65M | 39.44M | 32.99M | 2.17M | - |
| Capital lease obligations | 1.73M | 2.06M | 2.01M | 0.36M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -5.96100M | -7.84300M | -20.96760M | -0.80651M | - |
| Change to liabilities | - | 1.88M | 1.69M | 3.28M | 0.10M |
| Total cashflows from investing activities | - | -7.84300M | -20.96760M | -0.80651M | -0.85567M |
| Net borrowings | - | -2.21500M | 1.17M | -0.18731M | 0.28M |
| Total cash from financing activities | 0.45M | 31.99M | 1.33M | 49.12M | 30.99M |
| Change to operating activities | - | - | - | - | - |
| Net income | -26.93600M | -24.59500M | -20.31573M | -15.91115M | -9.87241M |
| Change in cash | -30.43700M | -1.55800M | -35.95690M | 36.46M | 20.60M |
| Begin period cash flow | 43.53M | 45.09M | 81.05M | 44.59M | 6.37M |
| End period cash flow | 13.10M | 43.53M | 45.09M | 81.05M | 44.59M |
| Total cash from operating activities | -24.98400M | -26.01100M | -16.27891M | -11.85228M | -9.53316M |
| Issuance of capital stock | 0.00000M | 34.21M | 0.16M | 49.31M | - |
| Depreciation | 3.11M | 2.56M | 1.60M | 0.64M | 0.33M |
| Other cashflows from investing activities | - | 0.03M | 0.20M | 0.31M | 0.07M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.34800M | -2.96700M | 0.77M | -0.42469M | -0.14076M |
| Change to account receivables | - | -3.17000M | -0.39401M | -0.55270M | -0.34284M |
| Sale purchase of stock | - | - | 0.16M | 49.31M | 46.06M |
| Other cashflows from financing activities | 2.02M | -0.37100M | 1.66M | -0.18731M | -1.72706M |
| Change to netincome | - | 0.28M | 0.38M | 1.11M | 0.40M |
| Capital expenditures | 3.27M | 6.12M | 0.58M | 1.12M | 0.72M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -2.75000M | -4.26200M | 2.06M | 2.31M | 1.07M |
| Stock based compensation | 1.40M | 2.56M | 0.73M | 1.55M | - |
| Other non cash items | 0.19M | 0.43M | -0.02410M | -0.29325M | - |
| Free cash flow | -28.25800M | -32.13300M | -16.85514M | -12.97008M | - |
Sector: Healthcare Industry: Medical Devices
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CREO Creo Medical Group PLC |
-0.08 0.42% | 19.17 | - | - | 4.53 | 1.91 | 3.91 | -4.68 |
| SN Smith & Nephew PLC |
0.40 0.04% | 973.20 | 53.70 | 14.27 | 1.75 | 2.26 | 2.21 | 13.21 |
| MXCT MaxCyte Inc |
10.00 3.03% | 340.00 | - | - | 10.41 | 2.15 | 6.75 | -6.5763 |
| NIOX NIOX Group PLC |
-1.525 2.41% | 61.67 | 32.00 | 20.75 | 7.92 | 3.40 | 7.31 | 28.40 |
| EKF EKF Diagnostics Holdings Plc |
-0.2 0.75% | 26.40 | - | - | 2.40 | 2.09 | 2.25 | -19.3996 |
Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.
Creo House, Chepstow, United Kingdom, NP16 5UH
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig Jonathan Gulliford | CEO & Exec. Director | 1971 |
| Prof. Christopher Paul Hancock | Founder, CTO & Exec. Director | 1968 |
| Mr. Richard John Rees ACA | CFO, Company Sec. & Exec. Director | 1977 |
| Mr. David Gerard Woods | Chief Commercial Officer & Exec. Director | 1966 |
| Mr. Phil Hales | Sales & Marketing Director | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...